Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Unveiling the Pathological Landscape of Intrauterine Adhesion: Mechanistic Insights and Exosome-Biomaterial Therapeutic Innovations

Qin Z., Yu Q., Long Y.

Narrative Review on Face & Skin, published in Int J Nanomedicine (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Int J Nanomedicine (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40785949
PMCID
PMC12335249
DOI
10.2147/ijn.s527637
Citations
13

Abstract (original English)

Intrauterine adhesion (IUA) is a fibrotic disorder caused by endometrial injury, characterized by structural damage and functional impairment of the endometrium, which severely impacts female reproductive health. The core pathology of IUA revolves around aberrant fibrosis, driven by intricate interactions among inflammation, epithelial-mesenchymal transition (EMT), and dysregulated cellular processes such as autophagy and ferroptosis. Inflammation acts as a pivotal initiator, directly activating fibrotic pathways or inducing EMT, thereby exacerbating fibrosis. Recent studies highlight the dual roles of autophagy and ferroptosis in IUA progression, where their dysregulation either mitigates or aggravates fibrotic outcomes, underscoring the complexity of its pathogenesis. Current treatments, such as transcervical resection of adhesions (TCRA), offer short-term anatomical restoration but fail to address high recurrence rates and insufficient endometrial regeneration. Exosomes have emerged as a promising cell-free therapeutic strategy, leveraging their bioactive cargo to modulate fibrosis, inflammation, and EMT. However, research on exosome-based therapies for IUA remains limited, particularly in targeting autophagy, ferroptosis, and their integration with biomaterials. Biomaterial-assisted exosome delivery systems, such as hydrogels and scaffolds, enhance therapeutic efficacy by e

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
EndometriumAnimalsHumansUterine DiseasesFibrosisBiocompatible MaterialsAutophagyFemaleTissue AdhesionsExosomes

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research